ABSTRACT
BACKGROUND: Psoriasis of the intertriginous, anogenital, and facial regions remains a therapeutic challenge, with current algorithms lacking a topical agent that exhibits both high efficacy and minimal side effects. OBJECTIVE: To assess the safety and efficacy of crisaborole 2% ointment-a nonsteroidal phosphodiesterase 4 inhibitor-in the treatment of intertriginous, anogenital, and facial psoriasis. METHODS: A double-blind, randomized, vehicle-controlled trial was conducted in 21 participants. Participants were randomized 2:1 to receive 4 weeks of twice-daily treatment with either crisaborole 2% ointment (n = 14) or vehicle ointment (n = 7), followed by 4 weeks of open-label treatment with crisaborole 2% ointment. Disease severity was measured by using the Target Lesion Severity Scale (TLSS). RESULTS: After 4 weeks, participants in the crisaborole group demonstrated 66% improvement compared with 9% in the vehicle group (P = .0011). Participants in the crisaborole group continued to experience improvement through the open-label phase, demonstrating 81% lesional improvement by week 8, with 71% of these participants achieving clinical clearance. There were no adverse events. LIMITATIONS: The study was limited to a single tertiary care center and small sample size. CONCLUSION: Treatment with crisaborole 2% ointment was well-tolerated and led to clinical improvement in participants with intertriginous, anogenital, or facial psoriasis.
Subject(s)
Boron Compounds/administration & dosage , Bridged Bicyclo Compounds, Heterocyclic/administration & dosage , Psoriasis/drug therapy , Adult , Aged , Aged, 80 and over , Anal Canal , Boron Compounds/adverse effects , Bridged Bicyclo Compounds, Heterocyclic/adverse effects , Double-Blind Method , Facial Dermatoses/drug therapy , Female , Genitalia , Humans , Male , Middle Aged , Ointments , Pharmaceutical Vehicles , Treatment OutcomeABSTRACT
Actinic keratosis (AK) develops on chronically sun-exposed skin and constitutes one of the most common diseases managed by dermatologists. The incidence of AKs continues to rise among aging as well as younger sun damaged populations worldwide, underscoring the importance of effective therapy options. Various treatments are available, including light-based therapies, topical therapies, and destructive therapies. Herein, we review the current management options for AKs and discuss emerging therapeutic agents. J Drugs Dermatol. 2019;18(5 Suppl 1):s161-166.
Subject(s)
Keratosis, Actinic/therapy , Cryosurgery , Dermatologic Agents/therapeutic use , Humans , Imiquimod/therapeutic use , Keratosis, Actinic/pathology , PhotochemotherapyABSTRACT
Atopic dermatitis affects up to 20% of children and continues to increase in prevalence. Effective disease control is aimed at decreasing symptoms and reducing the frequency of flares, which may be complicated by secondary bacterial infections. Although recent advances have produced a number of non-systemic treatment options, topical corticosteroids remain a fundamental component of treatment algorithms. J Drugs Dermatol. 2019;18(2 Suppl):s112-116.
Subject(s)
Anti-Bacterial Agents/administration & dosage , Coinfection/drug therapy , Dermatitis, Atopic/drug therapy , Desonide/administration & dosage , Glucocorticoids/administration & dosage , Administration, Cutaneous , Clinical Trials as Topic , Coinfection/microbiology , Critical Pathways/standards , Dermatitis, Atopic/complications , Dermatology/standards , Humans , Treatment OutcomeABSTRACT
Brodalumab, a fully human antibody of the interleukin-17 receptor, is highly effective in the treatment of moderate-to-severe plaque psoriasis. However, based on safety signals identified in clinical trials, brodalumab carries a boxed warning regarding possible risks of suicidal ideation and behavior (SIB). The validity of this link remains controversial, especially in the context of the psoriasis population as well as clinical trial data from other recently approved treatments. Herein, we critically examine the association between brodalumab and SIB. J Drugs Dermatol. 2018;17(8 Suppl):s29-34.
Subject(s)
Antibodies, Monoclonal/adverse effects , Dermatologic Agents/adverse effects , Drug Labeling/standards , Interleukin-17/antagonists & inhibitors , Mental Disorders/chemically induced , Antibodies, Monoclonal/administration & dosage , Antibodies, Monoclonal, Humanized , Clinical Trials as Topic/standards , Dermatologic Agents/administration & dosage , Drug Labeling/trends , Humans , Interleukin-17/metabolism , Mental Disorders/prevention & control , Mental Disorders/psychology , Psoriasis/drug therapy , Psoriasis/psychology , Suicide/trends , Suicide PreventionABSTRACT
BACKGROUND: Azelaic acid demonstrates anti-inflammatory, anti-oxidative, anti-comedogenic, and anti-microbial effects. Azelaic acid 20% cream is currently approved for the treatment of acne vulgaris, and azelaic acid 15% foam has recently been approved for rosacea. Given the favorable tolerability profile of foam preparations, it is reasonable to assume that azelaic acid 15% foam could serve as a viable treatment option for facial acne. OBJECTIVE: To examine the efficacy and safety of azelaic acid 15% foam in the treatment of moderate-to-severe facial acne Methods: Twenty subjects with moderate-to-severe facial acne vulgaris were enrolled in this two-center, open-label pilot study. All study subjects were treated with azelaic acid 15% foam for 16 weeks. Efficacy analyses were based on the change in facial investigator global assessment (FIGA) and changes in total, inflammatory, non-inflammatory lesion counts between baseline and week 16. RESULTS: There was a significant reduction in FIGA scores from baseline to week 16 (p = .0004), with 84% of subjects experiencing at least a 1 grade improvement, and 63% of subjects achieving a final grade of Clear or Almost Clear. All subjects experienced reductions in inflammatory and total lesion counts by week 16, and 89% of subjects experienced reductions in non-inflammatory lesions. Azelaic acid 15% foam was well tolerated, with almost all instances of erythema, dryness, peeling, oiliness, pruritus, and burning being of mild or trace degree, and most adverse effects resolving by the end of the study. CONCLUSION: Azelaic acid 15% foam is effective and safe in the treatment of facial acne vulgaris. Given the convenience of foam vehicles, azelaic acid 15% foam should be considered as a viable treatment option for this condition. J Drugs Dermatol. 2018;17(6):641-645.
Subject(s)
Acne Vulgaris/diagnosis , Acne Vulgaris/drug therapy , Dicarboxylic Acids/administration & dosage , Administration, Topical , Adolescent , Adult , Dermatitis/diagnosis , Dermatitis/etiology , Dicarboxylic Acids/adverse effects , Dicarboxylic Acids/chemistry , Drug Compounding , Erythema/chemically induced , Erythema/diagnosis , Face , Female , Humans , Pilot Projects , Treatment Outcome , Young AdultABSTRACT
Recurrent erythema multiforme with oralinvolvement is therapeutically challenging.Apremilast has been used with success in resolvingthe oral aphthae of Behçet disease, prompting theuse of the drug in patients with oral erosions fromerythema multiforme. Three patients with oralerythema multiforme were given apremilast at dosesof 30-60mg daily. Complete clearance of the lesionswere observed in all three patients, including thoserefractory to other standard therapies. Apremilast maypresent an effective option for recurrent erythemamultiforme for patients who have failed trials antiviraland immunosuppressive therapies.